First-in-human gene editing for lipid lowering: the initial results

Cardiovasc Res. 2024 Mar 30;120(4):e5-e8. doi: 10.1093/cvr/cvae037.
No abstract available

Keywords: Atherosclerotic cardiovascular disease; Clinical trial; Gene editing; Lipid-lowering therapy; PCSK9 inhibitor.

MeSH terms

  • Anticholesteremic Agents*
  • Cardiovascular Diseases*
  • Gene Editing
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors*
  • Lipids
  • PCSK9 Inhibitors
  • Proprotein Convertase 9 / genetics

Substances

  • Anticholesteremic Agents
  • PCSK9 Inhibitors
  • Lipids
  • Proprotein Convertase 9
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors